Insiders NeuBase Therapeutics, Inc.

Equities

NBSE

US64132K2015

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
0.4101 ^USD	+1.26%		-1.96%	-44.59%

Mar. 26	Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	MT
Mar. 26	US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NeuBase Therapeutics, Inc. Announces CEO Changes	Jan. 17	CI
Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away	23-10-20	CI
NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director	23-05-18	CI
NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board	23-05-16	CI
NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022	22-10-24	CI
NeuBase Therapeutics Plans to Restructure to Focus on Gene Editing, to Cut 60% of Workforce	22-10-17	MT
NeuBase Therapeutics, Inc. Announces Executive Changes	22-10-14	CI
NeuBase Therapeutics, Inc. Announces Promotion of William Mann to President	22-06-29	CI
NeuBase Therapeutics Names Todd Branning Chief Financial Officer	22-01-10	MT
NeuBase Therapeutics, Inc. Appoints Todd P. Branning as Chief Financial Officer	22-01-10	CI
NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors	22-01-05	CI
NeuBase Therapeutics : Chief Business & Strategy Officer Kia Motesharei to Resign	21-10-22	MT
Kia Motesharei Intends to Resign as Chief Business and Strategy Officer of Neubase Therapeutics, Inc., Effective on November 5, 2021	21-10-22	CI
Vascular Biogenics : VBL Therapeutics Names Sam Backenroth Chief Financial Officer	21-10-05	MT
Vascular Biogenics : VBL Therapeutics Appoints Sam Backenroth Chief Financial Officer	21-10-05	MT
Neubase Therapeutics, Inc. Appoints Anthony Rossomando as Chief Technology Officer	21-09-14	CI
NeuBase Therapeutics, Inc. Appoints Dr. Kia Motesharei as Chief Business and Strategy Officer	21-05-25	CI
NeuBase Therapeutics, Inc. Appoints Sandra Rojas-Caro as Chief Medical Officer, Effective May 24, 2021	21-05-20	CI
NeuBase Therapeutics, Inc. Appoints Gerald J. McDougall to Board of Directors	21-05-12	CI
NeuBase Therapeutics, Inc. Announces Board Changes	21-03-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders NeuBase Therapeutics, Inc.

Equities

NBSE

US64132K2015

Insiders

Filters